Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer

Wen Son Hsieh, Ross Soo, Bee Keow Pen, Thomas Loh, Difeng Dong, Donny Son, Lim Soon Wong, Simon Green, Judy Chiao, Chun Ying Cui, Yoke Fong Lai, Soo Chin Lee, Benjamin Mow, Richie Soong, Manuel Salto-Tellez, Boon Cher Goh

Research output: Contribution to journalArticle

Abstract

Cell cycle dysregulation resulting in expression of antiapoptotic genes and ncontrolled proliferation is a feature of undifferentiated nasopharyngeal carcinoma. The pharmacodynamic effects of seliciclib, a cyclin-dependent kinase (CDK) inhibitor, were studied in patients with nasopharyngeal carcinoma. Experimental Design: Patients with treatment-näive locally advanced nasopharyngeal carcinoma received seliciclib at 800 mg or 400 mg twice daily on daysl to 3 and 8 to 12. Paired tumor samples obtained at baseline and on day 13 were assessed by light microscopy, immunohisto-chemistry, and transcriptional profiling using real-time PGR low-density array consisting of a panel of 380 genes related to cell cycle inhibition, apoptosis, signal transduction, and cell proliferation. Results: At 800 mg bd, one patient experienced grade 3 liver toxicity and another had grade 2 vomiting; no significant toxicities were experienced in 13 patients treated at 400 mg bd. Seven of fourteen evaluable patients had clinical evidence of tumor reduction. Some of these responses were associated with increased tumor apoptosis, necrosis, and decreases in plasma EBV DNA posttreatment. Reduced protein expression of Mcl-1, cyclin D1, phosphorylated retinoblastoma protein pRB (T821), and significant transcriptional down-regulation of genes related to cellular proliferation and survival were shown in some patients posttreatment, indicative of cell cycle modulation by seliciclib, more specifically inhibition of cdk2/cyclin E, cdk7/cyclin H, and cdk9/cyclinT, Conclusions: Brief treatment with this regimen of seliciclib in patients with nasopharyngeal carcinoma is tolerable at 400 mg bd and associated with tumor pharmacodynamic changes consistent with cdk inhibition, and warrants further efficacy studies in this tumor.

Original languageEnglish (US)
Pages (from-to)1435-1442
Number of pages8
JournalClinical Cancer Research
Volume15
Issue number4
DOIs
StatePublished - Feb 15 2009

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer'. Together they form a unique fingerprint.

  • Cite this

    Hsieh, W. S., Soo, R., Pen, B. K., Loh, T., Dong, D., Son, D., Wong, L. S., Green, S., Chiao, J., Cui, C. Y., Lai, Y. F., Lee, S. C., Mow, B., Soong, R., Salto-Tellez, M., & Goh, B. C. (2009). Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer. Clinical Cancer Research, 15(4), 1435-1442. https://doi.org/10.1158/1078-0432.CCR-08-1748